论文部分内容阅读
弥漫性大B细胞型淋巴瘤是非霍奇金淋巴瘤(non-Hodgkin’s lymphomas,NHL)中最常见的亚型,其生物学行为属侵袭性。CHOP方案是治疗侵袭性B细胞型非霍奇金淋巴瘤的标准方案,5年总生存率为40%~50%[1]。老年人的弥漫性大B细胞型淋巴瘤治疗更富有挑战性,强烈的化疗可以改善年轻患者的
Diffuse large B cell lymphoma is the most common subtype in non-Hodgkin’s lymphomas (NHL), and its biological behavior is aggressive. The CHOP regimen is a standard regimen for aggressive B-cell non-Hodgkin’s lymphoma with a 5-year overall survival of 40% to 50% [1]. Treatment of diffuse large B-cell lymphoma in the elderly is more challenging and aggressive chemotherapy can improve the outcome of younger patients